

## CERTIFICATE OF ABRIDGEMENT

**RE:** Annual General and Special Meeting of Mydecine Innovations Group Inc. (the “**Corporation**”) to be held on September 20, 2021 (the “**Meeting**”).

---

With reference to National Instrument 54-101 – *Communication with Beneficial Owners of Securities of a Reporting Issuer* (“**NI 54-101**”) David Joshua Bartch, Chief Executive Officer of the Corporation hereby certifies for and on behalf of the Company, and not in his personal capacity and without personal liability, that:

- (a) in accordance with the requirements set out in section 2.20(a) of NI 54-101, arrangements have been made to have the proxy-related materials for the Meeting sent in compliance with the applicable timing requirements in section 2.9 and section 2.12 of NI 54-101;
- (b) in accordance with the requirements set out in section 2.20(b) of NI 54-101, arrangements have been made to carry out all of the requirements of NI 54-101 applicable to the Meeting, in addition to those described in paragraph (a) above; and
- (c) the Company is relying on section 2.20 of NI 54-101 to abridge the time periods prescribed in section 2.2(1) and 2.5(1) of NI 54-101 applicable to the Meeting.

**DATED** this 23<sup>rd</sup> day of August, 2021.

**MYDECINE INNOVATIONS GROUP INC.**

*(signed) David Joshua Bartch*

Per: \_\_\_\_\_

David Joshua Bartch  
Chief Executive Officer